Funding Opportunity RFA-MH-21-225 from the NIH Guide for Grants and Contracts. The shock and kill strategy is one of the commonly used approaches for targeting latent reservoirs in hopes to cure HIV-1. It is based on the concept of purposely inducing reactivation of latent reservoirs in ART (antiretroviral therapy)-treated individuals by using stimulatory agents. However, it has become increasingly evident that attempts at elimination of HIV-1 reservoirs through latency reactivating agents (LRA) -mediated reactivation alone may not be sufficient. Novel strategies such as immunotherapy and gene excision therapies to optimize the recognition and elimination of reservoir cells such are being conceptualized and researched. Immunotherapy strategies like therapeutic vaccines to enhance HIV-1-specific CTL (cytotoxic T-cell) response, Chimeric Antigen Receptor T-cells (CAR-T cells) therapies, broadly neutralizing antibodies, dual-affinity retargeting antibodies that not only bind to HIV-1 viral envelope antigen but also activate the CTL response, and immune modulators, such as anti-PD1 (programmed cell death protein-1) or anti-CTL4 antibodies, to correct the immune exhaustion noticed in ART-treated individuals are being developed. In addition to immunotherapy strategies, Recombinant TALEN or CRISPR/Cas9 gene editing molecules delivered to latently infected cells designed to induce cleavage at highly conserved regions of the integrated HIV provirus genome are being researched. However, majority of immunotherapy-based and gene editing based HIV eradication strategies are focused on the periphery. The brain presents a unique challenge where access is difficult and innovative strategies are needed to overcome the blood brain barrier. It is also important to understand the potential CNS toxicity of immunotherapy-based and gene-editing based approaches currently being tested in clinical trials

Notice NOT-MD-21-024 from the NIH Guide for Grants and Contracts

Notice NOT-AR-21-017 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-081 from the NIH Guide for Grants and Contracts

Experience with DNA sequence analysis software such as Geneious and/or command-line tools highly desirable. Bachelor?s degree in a biological science required;…
From University of Wisconsin–Madison - Fri, 21 May 2021 18:58:00 GMT - View all Madison, WI jobs

: Bio-Rad Laboratories, Inc.: Bio-Rad's Clinical Immunology Diagnostics Group is a multidisciplinary team developing products using our BioPlex 2200... Benicia, California

: Bio-Rad Laboratories, Inc.: Bio-Rad Clinical Diagnostics Group (CDG) is one of the leading global providers of tests for infectious and autoimmune... Benicia, California

Notice NOT-AI-21-053 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-028 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-133 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-132 from the NIH Guide for Grants and Contracts

£37,865-£45,359: Wellcome Sanger Institute: The Opportunity: We are looking for a senior bioinformatician (data manager), who has experience of handling large genomic datasets, to look after ... Hinxton, Cambridgeshire

Competitive Salary: EMBL: We are seeking an outstanding individual to lead the Literature Services team, responsible for running Europe PMC, at the European Bioin Europe

Notice NOT-AI-21-055 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-067 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-129 from the NIH Guide for Grants and Contracts

£60-62 per hour LTD : CK Group: CK Group are recruiting for a Senior Statistician to join a company in the Pharmaceutical industry at their site based in Cambridge on a contract... Cambridge

£45,000 - £55,000 per annum + stock option and benefits: Singular Talent: Do you want to work on cutting edge science using powerful tech and precision medicine to shape the future of health care? Oxfordshire

Deep experience of standard NGS bioinformatics toolsets. Genus’ R&D is a growing organization with focus on industry-leading science and technology to support…
From Genus Plc - Thu, 20 May 2021 20:09:57 GMT - View all DeForest, WI jobs